Every breakthrough in the fight against cancer is driven by technological innovation. From immunotherapy to artificial intelligence applied to diagnosis, the development of new medical solutions is crucial to improving the prevention, detection, and treatment of this disease.
In this context, the European Patent Office (EPO) has published the report New Frontiers in Oncology, in which it analyzes the impact of patents on the evolution of oncology. This study not only highlights the growth of innovation in this field but also the key role of European startups in the development of new therapies.
The Growth of Innovation in Cancer Technologies
One of the most significant findings in the report is the rapid growth of oncology technologies over the past decade. Since 2015, cancer-related patents have increased at an annual rate of 9.3 percent—more than triple the average for other technology sectors.
Key areas of innovation include:
- Cellular Immunotherapy
- Gene therapy
- Image Analysis
- Liquid Biopsies
- Healthcare Informatics
This growth reflects a significant increase in investment and efforts to develop new solutions for the prevention, diagnosis, and treatment of cancer.
Global Leadership in Oncology Patents: the U.S., China, and Europe
The report also examines the geographic distribution of patents in oncology. Between 2010 and 2021, the United States led the sector with 44.6% of cancer-related patent applications.
Although China lags behind the U.S. and Europe, it has shown remarkable growth, reinforcing its role as a key player in biomedical innovation.
Although Europe has fewer patents than the U.S. (with a 23.9% share), it stands out as a hub for startups specializing in cancer. With nearly 1,500 startups in this field, the continent has established itself as a place where innovation and collaboration between the public and private sectors are bearing fruit.
Despite this European leadership, the report also notes that the U.S. continues to lead in the number of startups with patents at an advanced stage, giving it an advantage in bringing new therapies to market.
Compiled by the author based on the report *New Frontiers in Oncology*
Spain: A Leader in Cancer Research and Intellectual Property
Spain plays a leading role in cancer innovation, thanks to the work of universities, hospitals, and public research organizations. According to data from the report:
- 57% of patented inventions in oncology in Spain come from public entities.
- If indirect patents (originating in the public sector but filed by companies) are included, the impact rises to 65.9%, far exceeding the European average of 34.9%.
In addition, Spain ranks eighth in Europe in terms of oncology patents, as well as in the number of startups specializing in cancer, with 69 emerging companies in this field.
These figures reflect the strong commitment of the Spanish innovation ecosystem to the fight against cancer and the strategic value of industrial property in knowledge transfer and the development of new therapies.
The Role of Patents in Bringing New Therapies to Market
The EPO report confirms that patents are an essential element in the fight against cancer. They protect innovation, encourage investment in research, and enable new therapies to reach the market.
For startups, intellectual property is a key factor that not only guarantees the commercial exclusivity of their developments but also makes it easier to secure funding and form strategic partnerships with large pharmaceutical companies.
Ultimately, the combination of scientific talent, investment, and patent protection is the key to continuing to make progress in oncology and improving the lives of millions of patients around the world.
Dr. Irene Gascón, Associate in the Patent Practice Group at Elzaburu